Author
Listed:
- German Amadeo Erhardt
(Universidad Abierta Interamericana, Facultad de Medicina y Ciencias de la Salud. Rosario, Argentina)
- Mónica y Taborda
(Universidad Abierta Interamericana, Facultad de Medicina y Ciencias de la Salud. Rosario, Argentina)
Abstract
Introduction: Stroke is the third leading cause of death and the leading cause of disability in Argentina. Eighty per cent of strokes are ischaemic. Stroke requires the use of a standardised scale, such as the National Institute of Health Stroke Scale (NIHSS), in order to document possible deficits and their severity, as well as to make decisions regarding the treatment to be administered. Objective: To calculate the frequency with which the NIHSS scale is used within the window period as a method of diagnosing ischemic stroke in patients attending the Eva Perón Hospital (Granadero Baigorria, Santa Fe) in 2023. Materials and methods: A quantitative, observational study was conducted with a descriptive, cross-sectional, retrospective design. The population consisted of all patients of both sexes diagnosed with ischaemic stroke who attended a post-hospitalisation check-up at the outpatient clinic of the neurology department of Eva Perón Hospital. Patients over 18 years of age diagnosed with ischaemic stroke during the study period were included. The medical records of patients diagnosed with ischaemic stroke were used as a secondary data source. Results: A sample of 20 patients diagnosed with ischaemic stroke was analysed. Of these, only 30% were diagnosed within the therapeutic window, but only 20% of the total number of patients were classified based on the NIHss scale at admission. Seventy per cent of patients had an NIHss score between 4 and 24 points, which allowed them to be classified as possible candidates for fibrinolytic treatment, but only 10% of patients were able to access this treatment and 85% were left with serious sequelae. Conclusions: The NIHss scale is rarely used as a diagnostic method for ischaemic stroke within a window period. The lack of this data at the appropriate time hinders decision-making and makes it less likely that fibrinolytic treatment will be administered at the right time and that patients will have a better outcome.
Suggested Citation
Handle:
RePEc:cwh:ijneur:v:58:y:2024:id:120
DOI: 10.62486/ijn2024120
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:cwh:ijneur:v:58:y:2024:id:120. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Dr. Andrew Alberto López Sánchez (email available below). General contact details of provider: https://ijneurology.org/index.php/ijn .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.